Aridis Pharmaceuticals Appoints Paul Mendelman As Interim Chief Medical Officer

Aridis Pharmaceuticals, Inc., a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening bacterial infections, announced today that it has appointed Paul Mendelman, MD as interim Chief Medical Officer (CMO). Dr. Mendelman replaces Dr. Wolfgang Dummer who has departed the company for personal reasons.

“It is a pleasure to welcome Dr. Mendelman, a recognized leader in the development of new treatments for infectious diseases to the Aridis team. His expertise comes at a critical juncture for the company given we are advancing multiple clinical programs, including our lead Phase 3 antibody program, AR-301, which can benefit from additional infectious disease expertise particularly in critical care (ICU) settings,” commented Vu Truong, Ph.D., Chief Executive Officer of Aridis Pharmaceuticals.

Dr. Mendelman brings to Aridis a prolific career in infectious diseases across industry and academia spanning over 30 years with board certification in pediatrics and pediatric infectious diseases. He has held senior clinical development positions at leading companies such as Takeda Vaccines (Vice President, Medical), MedImmune (Vice President & Therapeutic Area Leader, Clinical Development), and Merck (Director, Clinical Research Infectious Diseases). From 1996 to 2005, he managed the clinical development group for FluMist®, the live attenuated intranasal influenza vaccine, licensed initially in the U.S. for the 2003-04 season.

Dr. Mendelman earned his BS and MD degrees at The Ohio State University, and completed post-graduate training at the University of Colorado Medical Center in Denver. His infectious disease fellowship at the University of Washington, School of Medicine, and Seattle Children’s Hospital was followed by his joining that faculty and later serving as consulting Professor of Pediatrics at Stanford University School of Medicine. He has published over 100 articles in peer-reviewed journals and authored many published book chapters.

Dr. Mendelman’s initial priority will be to manage the Company’s ongoing Phase 3 for AR-301 in patients with ventilator associated pneumonia (VAP) and the ongoing Phase 1/2a for AR-501 in patients with cystic fibrosis. He will also work closely with the Aridis team in overseeing the ongoing analysis of results from the Company’s recent AR-105 Phase 2 for the treatment of VAP caused by gram-negative Pseudomonas aeruginosa.

“I am very pleased to have the opportunity to work on these innovative anti-infectives, which are clearly differentiated from antibiotics and have significant potentials to impact the landscape of infectious diseases treatments,” commented Dr. Mendelman. – PR Newswire

Share this:

Related Post

Stay Updated on Medical Equipment and Devices industry.
Receive our Daily Newsletter.